Slide 1: 2011 Preliminary results, Outlook for 2012
2011 Preliminary results Outlook for 2012 9 FEBRUARY 2012
Slide 2: Full year 2011 highlights
Full year 2011 highlights A very productive year • Revenue € 762.0 million, up 4.7%. • Operating income (EBIT) € 163.5 163 5 million or 21.5% 21 5% of sales sales, up 5 6% 5.6%. • Net income € 116.5 million or 15.3% of sales, up 7.2%. • Acquisition of Procto Glyvenol for the markets of Central and E
Slide 3: Composition of revenue
Composition of revenue New emerging markets and new products driving growth (million Euro) 2011 2010 Change % Italy 217.7 197.0 10.5 France 128.7 139.9 (8.0) Germany 66.2 63.3 4.6 Portugal 34.4 36.3 (5.3) S i Spain 31 8 31.8 29 6 29.6 74 7.4 United Kingdom 7.6 9.9 (22.5) Other Western European count
Slide 4: A growing presence in Eastern Europe and Turkey
A growing presence in Eastern Europe and Turkey Portugal 4.7% Spain 4.3% UK 1.0% Germany 9.0% Other W. European countries 2.7% Russia, Turkey, other CEE 11.7% France 17.5% Other international sales 19.4% (sales to licensees and exports) Italy 29.7% Data: Full year 2011 Pharmaceutical revenue € 733.6
Slide 5: Main product sales
Main product sales Corporate products including orphan drugs now account for 42.2% of sales (million Euro) 2011 2010 Change % Zanidip® (lercanidipine) 124.7 148.7 (16.1) ® ((lercanidipine+enalapril) p Zanipress p p ) 41.6 31.7 31.4 Urorec® (silodosin) 19.8 2.1 n.s. Livazo® (pitavastatin) 6.8 ‐ n.s.
Slide 6: A richer product portfolio
A richer product portfolio Zanipress 5.5% Urorec 2.6% Other corporate products 8.7% Zanidip 16.4% Orphan drugs 9 9.1% 1% Pharmaceutical chemicals 3.7% Subsidiaries’ local product Other revenue 3.7% portfolios 50.3% Entact®/Elopram® 6% ((escitalopram/citalopram) p / p ) ‐ Italyy Methadone ‐ France 3%
Slide 7: Full year 2011 results
Full year 2011 results Healthy sales and earnings growth (million Euro) 2011 2010 Change % Revenue 762.0 728.1 4.7 Gross Profit 502.1 488.1 2.9 as % of revenue 65 9 65.9 67 0 67.0 SG&A Expenses 277.5 260.5 6.5 as % of revenue 36.4 35.8 R&D Expenses 56.0 68.8 (18.7) as % of revenue 7.3 9.5 Other Inco
Slide 8: Financial position and Shareholders' equity
Financial position and Shareholders’ equity Net debt following the acquisition of Frik Ilaç, payment of dividends and other investments (million Euro) 31 Dec 2011 31 Dec 2010 Change Cash and short‐term financial 105 2 105.2 161 7 161.7 (56 5) (56.5) investments Bank overdrafts and short‐term loans (
Slide 9: Financial projections
Financial projections 2011 targets exceded 2011 2012 (million Euro) Actuall Targets Revenue 762.0 810‐830 Operating income (EBIT) 163.5 160‐170 Net Income 116.4 110‐120 9
Slide 10: Company declarations, disclaimers and profile
Company declarations, disclaimers and profile DECLARATION BY THE MANAGER RESPONSIBLE FOR PREPARING THE COMPANY’S FINANCIAL REPORTS The manager responsible for preparing the company’s financial reports Fritz Squindo declares, pursuant to paragraph 2 of Article 154‐bis of the Consolidated Law on Finan